Effectiveness and Cost-Effectiveness of Adjunctive Personalised Psychosocial Intervention in Treatment-Resistant Opioid Agonist Therapy: A Pragmatic, Open-Label, Randomised Controlled Trial

Psychosocial Intervention ◽

Controlled Trial ◽

Treatment Resistant ◽

Agonist Therapy ◽

Open Label ◽

Opioid Agonist ◽

Opioid Agonist Therapy ◽

Efficacy and cost-effectiveness of an adjunctive personalised psychosocial intervention in treatment-resistant maintenance opioid agonist therapy: a pragmatic, open-label, randomised controlled trial

The Lancet Psychiatry ◽

10.1016/s2215-0366(19)30097-5 ◽

2019 ◽

Vol 6 (5) ◽

pp. 391-402 ◽

Cited By ~ 6

Author(s):

John Marsden ◽

Garry Stillwell ◽

Kirsty James ◽

James Shearer ◽

Sarah Byford ◽

...

Keyword(s):

Cost Effectiveness ◽

Psychosocial Intervention ◽

Controlled Trial ◽

Treatment Resistant ◽

Agonist Therapy ◽

Open Label ◽

Opioid Agonist ◽

Opioid Agonist Therapy ◽

Effectiveness of adjunctive, personalised psychosocial intervention for non-response to opioid agonist treatment: Study protocol for a pragmatic randomised controlled trial

Contemporary Clinical Trials ◽

10.1016/j.cct.2016.12.003 ◽

2017 ◽

Vol 53 ◽

pp. 36-43 ◽

Cited By ~ 9

Author(s):

John Marsden ◽

Garry Stillwell ◽

Jennifer Hellier ◽

Anne Marie Brown ◽

Sarah Byford ◽

...

Keyword(s):

Pragmatic Randomised Controlled Trial

Study Protocol ◽

Psychosocial Intervention ◽

Controlled Trial ◽

Opioid Agonist ◽

Opioid Agonist Treatment ◽

Randomised Controlled ◽

The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial

The Lancet ◽

10.1016/s0140-6736(21)00247-6 ◽

2021 ◽

Vol 397 (10282) ◽

pp. 1363-1374 ◽

Cited By ~ 1

Author(s):

Anthony Marson ◽

Girvan Burnside ◽

Richard Appleton ◽

Dave Smith ◽

John Paul Leach ◽

...

Keyword(s):

Cost Effectiveness ◽

Focal Epilepsy ◽

Controlled Trial ◽

Newly Diagnosed ◽

Open Label ◽

Multicentre Phase ◽

The clinical and cost-effectiveness of corticosteroid injection versus night splints for carpal tunnel syndrome (INSTINCTS trial): an open-label, parallel group, randomised controlled trial

The Lancet ◽

10.1016/s0140-6736(18)31572-1 ◽

2018 ◽

Vol 392 (10156) ◽

pp. 1423-1433 ◽

Cited By ~ 21

Author(s):

Linda S Chesterton ◽

Milica Blagojevic-Bucknall ◽

Claire Burton ◽

Krysia S Dziedzic ◽

Graham Davenport ◽

...

Keyword(s):

Cost Effectiveness ◽

Carpal Tunnel Syndrome ◽

Corticosteroid Injection ◽

Controlled Trial ◽

Open Label ◽

Parallel Group ◽

Tunnel Syndrome ◽

Randomised Controlled ◽

Night Splints

The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial

The Lancet ◽

10.1016/s0140-6736(21)00246-4 ◽

2021 ◽

Vol 397 (10282) ◽

pp. 1375-1386 ◽

Cited By ~ 1

Author(s):

Anthony Marson ◽

Girvan Burnside ◽

Richard Appleton ◽

Dave Smith ◽

John Paul Leach ◽

...

Keyword(s):

Cost Effectiveness ◽

Controlled Trial ◽

Newly Diagnosed ◽

Open Label ◽

Multicentre Phase ◽

Faculty Opinions recommendation of The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.739920891.793585363 ◽

2021 ◽

Author(s):

Adam Hartman

Keyword(s):

Cost Effectiveness ◽

Controlled Trial ◽

Newly Diagnosed ◽

Open Label ◽

Multicentre Phase ◽

39-LB: Individualised Screening for Diabetic Retinopathy: The ISDR Study—A Randomised Controlled Trial of Safety, Efficacy, and Cost-Effectiveness

Diabetes ◽

10.2337/db19-39-lb ◽

2019 ◽

Vol 68 (Supplement 1) ◽

pp. 39-LB

Author(s):

DEBORAH MARY BROADBENT ◽

AMU WANG ◽

CHRISTOPHER P. CHEYNE ◽

JAMES G. LATHE ◽

IRENE M. STRATTON ◽

...

Keyword(s):

Diabetic Retinopathy ◽

Cost Effectiveness ◽

Controlled Trial ◽

A randomised controlled trial comparing the Cost-effectiveness of blastocyst (Day 5/6 ) versus cleavage stage (Day 3) embryo transfers in IVF-ICSI Cycles in developing countries

10.26226/morressier.5912d9efd462b8029238677f ◽

2017 ◽

Author(s):

Randhir Singh

Keyword(s):

Developing Countries ◽

Cost Effectiveness ◽

Controlled Trial ◽

Cleavage Stage ◽

Randomised Controlled ◽

The Cost ◽

Day 3 Embryo

A MULTICENTRE DOUBLE-BLIND RANDOMISED CONTROLLED TRIAL TO ASSESS THE CLINICAL- AND COST-EFFECTIVENESS OF FACET-JOINT INJECTIONS IN PATIENTS WITH NON-SPECIFIC LOW BACK PAIN: A FEASIBILITY STUDY

10.26226/morressier.59ad4811d462b80290b53a8a ◽

2017 ◽

Author(s):

Ahmad Alia

Keyword(s):

Low Back Pain ◽

Back Pain ◽

Cost Effectiveness ◽

Facet Joint ◽

Controlled Trial ◽

Low Back ◽

Double Blind ◽

Randomised Controlled ◽

Joint Injections

Faculty Opinions recommendation of Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1166102.628092 ◽

2009 ◽

Author(s):

Jim Orr ◽

Fadi Abu Shahin

Keyword(s):

Ovarian Cancer ◽

Controlled Trial ◽

Advanced Ovarian Cancer ◽

Open Label ◽

Phase 3 ◽

Dose Dense ◽